Financial Survey: Insulet (NASDAQ:PODD) versus Lucid Diagnostics (NASDAQ:LUCD)

Insulet (NASDAQ:PODD) and Lucid Diagnostics (NASDAQ:LUCD) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Insider and Institutional Ownership

74.0% of Lucid Diagnostics shares are held by institutional investors. 0.5% of Insulet shares are held by insiders. Comparatively, 8.8% of Lucid Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Insulet has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Insulet and Lucid Diagnostics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	0	2	13	0	2.87
Lucid Diagnostics	0	0	4	1	3.20

Insulet presently has a consensus target price of $277.13, suggesting a potential downside of 2.31%. Lucid Diagnostics has a consensus target price of $3.63, suggesting a potential upside of 129.43%. Given Lucid Diagnostics’ stronger consensus rating and higher probable upside, analysts plainly believe Lucid Diagnostics is more favorable than Insulet.

Valuation and Earnings

This table compares Insulet and Lucid Diagnostics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$1.70 billion	11.72	$206.30 million	$5.84	48.58
Lucid Diagnostics	$2.43 million	38.58	-$52.67 million	($1.14)	-1.39

Insulet has higher revenue and earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Insulet and Lucid Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Insulet	21.22%	27.98%	9.16%
Lucid Diagnostics	-1,069.87%	N/A	-123.54%

Summary

Insulet beats Lucid Diagnostics on 8 of the 15 factors compared between the two stocks.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

About Lucid Diagnostics

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.